Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours

[1]  P. Houghton,et al.  Potentiation of neuroblastoma metastasis by loss of caspase-8 , 2006, Nature.

[2]  Miki Ohira,et al.  Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model. , 2004, Cancer letters.

[3]  J. Joseph,et al.  Restoration of TRAIL‐Induced Apoptosis in a Caspase‐8‐Deficient Neuroblastoma Cell Line by Stable Re‐expression of Caspase‐8 , 2003, Annals of the New York Academy of Sciences.

[4]  S. Sugano,et al.  Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets , 2003, Oncogene.

[5]  W. Gerald,et al.  Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. , 2003, Cancer research.

[6]  S. Fulda,et al.  Apoptosis pathways in neuroblastoma therapy. , 2003, Cancer letters.

[7]  J. Lunec,et al.  The p53 pathway and its inactivation in neuroblastoma. , 2003, Cancer letters.

[8]  A. Donfrancesco,et al.  Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. El-Deiry,et al.  Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.

[10]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[11]  J. Qin,et al.  Parc A Cytoplasmic Anchor for p53 , 2003, Cell.

[12]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[13]  J. Herman,et al.  Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. , 2002, Cancer research.

[14]  Hiroyuki Shimada,et al.  Morphologic features of neuroblastoma (Schwannian stroma‐poor tumors) in clinically favorable and unfavorable groups , 2002, Cancer.

[15]  D. Stram,et al.  International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors , 2001, Cancer.

[16]  A. Nakagawara,et al.  Trk receptor tyrosine kinases: a bridge between cancer and neural development. , 2001, Cancer letters.

[17]  J. Tschopp,et al.  Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. , 2000, Cancer research.

[18]  F. Behm,et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.

[19]  K K Matthay,et al.  The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.

[20]  Hiroyuki Shimada,et al.  Terminology and morphologic criteria of neuroblastic tumors , 1999, Cancer.

[21]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[22]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[23]  G. Evan,et al.  A matter of life and cell death. , 1998, Science.

[24]  D. Stram,et al.  Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. , 1995, Journal of the National Cancer Institute.

[25]  C. Thompson,et al.  Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. , 1995, Cancer research.

[26]  M. Akami,et al.  Bcl-2 oncoprotein expression and apoptosis in neuroblastoma. , 1995, Journal of pediatric surgery.

[27]  U. Moll,et al.  Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Nakagawara,et al.  Relationship between bcl-2 and myc gene expression in human neuroblastoma. , 1995, Cancer letters.

[29]  C. Bloch,et al.  Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. , 1994, Cancer research.

[30]  G. Núñez,et al.  Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. , 1993, The American journal of pathology.

[31]  J. Pelletier,et al.  Absence of p53 gene mutations in primary neuroblastomas. , 1993, Cancer research.

[32]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[33]  C. Dominici,et al.  Association of near-diploid DNA content and N-myc amplification in neuroblastomas , 1989, Clinical & Experimental Metastasis.

[34]  A. Evans,et al.  Spontaneous regression of neuroblastoma. , 1976, National Cancer Institute monograph.

[35]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[36]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[37]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[38]  J. Hoehner,et al.  Proliferation and apoptosis in neuroblastoma: subdividing the mitosis-karyorrhexis index. , 1995, European journal of cancer.

[39]  G. Majno,et al.  Apoptosis, oncosis, and necrosis. An overview of cell death. , 1995, The American journal of pathology.

[40]  D.,et al.  Regression Models and Life-Tables , 2022 .